Human Papillomavirus Vaccination
8
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Stories to Prevent (StoP) HPV Cancers
HPV Vaccine Reminders - SEARCH II Study
SMS HPV Vaccine Reminders
Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi
Testing the Persuasiveness of Pro-inoculation Arguments
Can an Educational Intervention Targeting General Practitioners Increase HPV Vaccination Coverage in AuRA_Lyon (France)
County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana
Parent-son-provider Decision-making About HPV Vaccination